Solid Biosciences INC

Solid Biosciences Inc. held its Annual Meeting of Stockholders on June 10, 2026, where shareholders elected directors, ratified auditor appointments, and approved a significant increase in authorized common stock.

Solid Biosciences Inc. announced a strategic realignment of its Board of Directors to ensure balanced class membership, with Ilan Ganot transitioning to a new directorship.

Solid Biosciences Inc. announced a private placement raising $240 million, extending its cash runway into the first half of 2028.

Solid Biosciences announced positive interim data from its INSPIRE DUCHENNE trial, Q3 2025 financial results, and an extended cash runway into H1 2027.

Solid Biosciences Inc. announced that its stockholders approved a significant increase in authorized common stock and an amendment to its equity incentive plan, alongside the election of directors and ratification of auditors at its Annual Meeting.

Solid Biosciences has filed a prospectus supplement to offer and sell up to $85 million of its common stock.

Solid Biosciences reported a wider net loss in Q1 2026 due to increased R&D investments, but maintained a robust cash position and advanced its gene therapy pipeline.

Solid Biosciences announced positive interim data from its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, showing promising microdystrophin expression and cardiac benefits.

Solid Biosciences reports increased R&D spend and net losses in Q2 2025, but extends cash runway into H1 2027 following a significant capital raise and positive clinical progress for its gene therapy candidates.

Solid Biosciences reports positive initial data from its Phase 1/2 INSPIRE DUCHENNE trial and anticipates initiating a Phase 1b clinical trial of SGT-212 in the second half of 2025.

Solid Biosciences reported its third quarter 2024 financial results, highlighting progress in its gene therapy programs and a recent asset acquisition.

Solid Biosciences Inc. reported progress in its Phase 1/2 INSPIRE Duchenne trial for SGT-003, alongside advancements in its broader gene therapy pipeline for neuromuscular and cardiac diseases in its Q2 2024 results.

Solid Biosciences reports positive interim clinical data for SGT-003 in Duchenne, initiates Phase 3, and secures significant financing to extend its cash runway into mid-2028.

Solid Biosciences announces positive early data from its INSPIRE DUCHENNE trial and FDA clearance for its Friedreich's ataxia treatment, marking significant progress in its rare disease pipeline.

Solid Biosciences has introduced a new stock incentive plan aimed at attracting and retaining individuals who can significantly contribute to the company's growth.

Solid Biosciences Inc. reports that Director Ilan Ganot was granted stock options for 77,500 shares.

Perceptive Advisors LLC, along with related entities and individuals, has reported the acquisition of stock options for Solid Biosciences Inc. common stock.

Director Georgia Keresty of Solid Biosciences Inc. acquired stock options for 77,500 shares, with an exercise price of $6.61, as part of a compensation plan.

Solid Biosciences Inc. reports that Director Martin I. Freed acquired 77,500 stock options with an exercise price of $6.61.

Clare Kahn, a Director at Solid Biosciences Inc., acquired 77,500 stock options with an exercise price of $6.61.

Solid Biosciences Inc. reports that Director Lynne Marie Sullivan acquired 77,500 stock options on June 10, 2026, with an exercise price of $6.61.

Solid Biosciences Inc. is holding its annual meeting on June 12, 2025, seeking stockholder votes on director elections, auditor ratification, and amendments to the company's certificate of incorporation and equity incentive plan.

Solid Biosciences is asking stockholders to approve an increase in authorized common stock and an amendment to its equity incentive plan at the 2025 annual meeting.

Solid Biosciences is holding its annual meeting on June 11, 2024, seeking stockholder approval for several key proposals, including increasing authorized shares and expanding the equity incentive plan.

Solid Biosciences is asking stockholders to vote on proposals to increase authorized common stock and amend its equity incentive plan at the upcoming annual meeting.

RA Capital Management has increased its beneficial ownership in Solid Biosciences Inc. through recent open market and ATM offering purchases.

RA Capital Management and its affiliates increased their beneficial ownership in Solid Biosciences Inc. to 9.9% through recent open market purchases totaling over $23.7 million.

RA Capital Management and its affiliates have increased their beneficial ownership in Solid Biosciences Inc. to 9.9% through recent open market purchases.

Bain Capital-affiliated entities have significantly increased their beneficial ownership in Solid Biosciences Inc. to 9.99% following the company's recent $200 million public offering of common stock and pre-funded warrants.

RA Capital Management and its affiliates have increased their beneficial ownership in Solid Biosciences Inc. to 9.9% following the purchase of pre-funded warrants for approximately $15 million.

Perceptive Advisors LLC and its affiliates have significantly increased their beneficial ownership in Solid Biosciences Inc. to 15.6% of outstanding common stock, acquiring 5 million shares for $20.2 million in a recent underwritten offering.

BlackRock, Inc. has reported beneficial ownership of 6,419,730 shares, representing 6.5% of the outstanding common stock of Solid Biosciences Inc.

Invus Public Equities, L.P. and affiliated entities have reported beneficial ownership of 10,066,682 shares, representing 9.99% of Solid Biosciences Inc.'s outstanding common stock as of March 31, 2026.

BlackRock, Inc. has disclosed a beneficial ownership of 4.7% in Solid Biosciences Inc. as of March 31, 2026, holding 4,578,650 shares.

Adage Capital Management and its principals report a 1.8% beneficial ownership stake in Solid Biosciences Inc. as of December 31, 2025.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, reported a 5.14% beneficial ownership stake in Solid Biosciences Inc.

Commodore Capital LP and Commodore Capital Master LP have reported a 0.0% beneficial ownership in Solid Biosciences Inc., indicating a full divestment of their previous stake.